This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.

Browse

Trestolone

Extensively Studied

Population Council male contraceptive candidate — that's the giveaway.

Aliases (5)
MENT · 7α-methyl-19-nortestosterone · 7-MENT · Trestolone Acetate · Trestolone Enanthate
TYPICAL DOSE
Contraceptive (Population Council): ~400 μg/day…
Weekly
ROUTE
Intramuscular injection (oil)
Intramuscular
CYCLE
8-12 weeks max
Cycle length (8-16 wk)
STORAGE
Room temp; protect from light
Room temp

Overview

What is Trestolone?

Trestolone (7α-methyl-19-nortestosterone, MENT) is a synthetic anabolic-androgenic steroid investigated as a male contraceptive and androgen replacement. It is approximately 10x more potent than testosterone in suppressing gonadotropins and significantly more anabolic per mg.

Key Benefits

Strong anabolic and androgenic effects with potent suppression of LH/FSH (originally for male contraception), effective in androgen replacement at low doses, and produces estradiol via aromatization (preserving estrogen-mediated benefits like bone and lipid health).

Mechanism of Action

Binds the androgen receptor with high affinity. Crucially, MENT cannot be 5-alpha-reduced (the 19-nor structure resists conversion in prostate/scalp), and it aromatizes to a potent estrogen (7α-methyl-estradiol). Result: strong central HPG suppression and skeletal muscle anabolism without the prostate/hair concerns of testosterone.

Pharmacokinetics

·
PeakHalf-life
Approximate curve — visual aid only, not data-precise PK
Vial inspection & sterile draw AAS oil

AAS oil arrives pre-suspended in carrier oil — no BAC water needed. Inspect for clarity, color, and crashed compound (cold storage can crystallize). Warm vial in palm or under hot tap before draw.

Steps
  1. 1 Wipe vial stopper with isopropyl alcohol.
  2. 2 Warm vial 30-60s in palm if oil is cold/cloudy.
  3. 3 Draw with 18g needle into 22-25g pin barrel for IM, or 27-29g for sub-Q.
  4. 4 Tap out air bubbles, expel a small drop, then inject at chosen site.
Open dose calculator for Trestolone
Cycle structure & PCT AAS
Ester
acetate
Frequency
daily
PCT
Required
Phase 1 — On cycle

Ramp dose over week 1, hold steady through cycle weeks. Track baseline labs (TT/FT/E2/SHBG/HCT/lipids/LFTs) at week 0; recheck at week 4 and end-of-cycle.

Phase 2 — Bridge / cease

On the last dose, the ester clears over its half-life window (acetate = est. ~7 days). PCT begins after the active compound has cleared.

Phase 3 — PCT (post-cycle therapy)

Standard PCT is enclomiphene 12.5-25 mg/day or clomid 50/50/25/25 over 4 weeks (or nolvadex 20/20/10/10). HCG bridge optional during cycle to preserve testicular volume + faster restart. Bloodwork at PCT week 4 + 8 to confirm HPG axis recovery (LH, FSH, TT back to baseline).

Research Indications

Most Effective

19-nor structure

Like nandrolone, the 19-carbon is removed. Reduces androgenic-to-anabolic ratio shift, weakens DHT-mediated effects.

Effective

7α-methyl group

Blocks 5α-reductase conversion (no DHT, no scalp/prostate DHT exposure) AND blocks 3α-HSD oxidative deactivation. Result: extremely high …

Investigational

Aromatization

Unlike most 19-nors, MENT aromatizes to 7α-methylestradiol — a potent estrogen. AI's are still required to manage E2; this is NOT a "dry"…

Investigational

Progesterone receptor

Weak PR binding (less than nandrolone), but enough to potentiate suppression alongside the estrogen feedback. This is part of why suppres…

Investigational

HPG-axis effect

Within days of supraphysiologic dosing, LH and FSH crash. Endogenous testosterone production halts. Intratesticular testosterone drops to…

Investigational

Potency

~10× testosterone by mass on AR binding/anabolic assays. Translation: 1 mg MENT ≈ 10 mg testosterone for tissue-level AR signaling.

Research Protocols

Disclaimer: These are commonly discussed research protocols and not medical advice.

Goal:Contraceptive (Population Council)
Dose:400 μg/day via subdermal implant
Frequency:
Solo:
Cycle:
Goal:Bodybuilding (gray-market, NOT clinical)
Dose:50-100 mg/week trestolone acetate (TNE-style daily injections of 10-15 mg/day common due to short ester half-life)
Frequency:
Solo:
Cycle:
Goal:TRT replacement (experimental)
Dose:25-50 mg/week — controversial
Frequency:
Solo:
Cycle:

Peptide Interactions

Any other AAS
Avoid

additive HPG suppression, additive lipid/cardiovascular damage

Other 19-nors (nandrolone, trenbolone)
Avoid

overlapping PR binding, more progestogenic gyno risk

Oral 17α-alkylated AAS (oxandrolone, etc.)
Avoid

additive lipid/hepatic stress

Quality Indicators

White, fluffy cake (peptides)

Lyophilized peptide should appear as a white, fluffy "cake" filling most of the vial bottom. Indicates proper freeze-drying.

Clear solution after reconstitution

After mixing with bacteriostatic water, the solution should be crystal clear with no particles or cloudiness.

!

Slight clumping acceptable

Small clumps that fully dissolve with gentle swirling are normal — shipping can cause minor compaction.

Collapsed or melted powder

Powder that looks collapsed, melted, or stuck to vial sides may have been heat-damaged in transit.

Cloudy or particulate solution

Persistent cloudiness or visible particles after gentle mixing indicate degraded or contaminated material.

What to Expect

  • Week 1-2
    Frontload phase. Strength gains start; appetite up.
  • Week 3-4
    Visible muscle fullness and recovery acceleration.
  • Week 5-8
    Peak performance window. Monitor blood pressure + libido.
  • Post-cycle
    PCT week 1-4. Bloodwork at week 6 post-cycle.

Side Effects & Safety

  • Common (>10% users):
    • Full HPG-axis shutdown (universal)
    • Libido oscillation
    • Acne (high AR potency)
    • Water retention / mild gyno risk if no AI
    • Lipid changes — HDL crash, LDL elevation (typical 19-nor profile, possibly worse due to potency)
  • Less common (1-10%):
    • Mood lability, aggression
    • Hair shedding (despite no DHT — AR signaling at follicle still occurs)
    • Hematocrit elevation
    • Sleep disruption, night sweats
  • Rare-serious (<1% but worth knowing):
    • Gynecomastia requiring surgical correction
    • Prolonged HPG-axis recovery (months to never returning to baseline) — risk increases with cycle length, age at first use, prior cycles
    • Cardiovascular: lipid-mediated atherogenic shift; LVH on chronic high-dose
    • Hepatotoxicity is LOW — MENT is not C17α-alkylated, so injectable use is liver-friendly (unlike oxandrolone). Transdermal/subdermal forms are also liver-sparing.
  • Specific watch periods: First 4-8 weeks for E2 management; entire cycle + 6+ months post for HPG-axis recovery
Was this helpful?
Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources

Related compounds

Cross-referenced from Trestolone

More in AAS · Oil injectable

7 compounds in bucket